<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01719705</url>
  </required_header>
  <id_info>
    <org_study_id>R/60</org_study_id>
    <nct_id>NCT01719705</nct_id>
  </id_info>
  <brief_title>Effects of Pregabalin on Post-cesarean Pain</brief_title>
  <official_title>Efficacy of Preoperative Pregabalin on the Post-caesarean Pain; a Dose-response Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-cesarean pain management is essential for early mobilization of the mother so that she&#xD;
      becomes able to care of her newborn. There choices for postoperative analgesia include&#xD;
      spinal, systemic, or both opioids, non-steroidal anti-inflammatory drugs (NSAIDs), local&#xD;
      anesthetic infiltrations of the wound, or transverse abdominis plane blocks, which are&#xD;
      determined by drug availability, regional and individual preferences, resource limitations&#xD;
      and financial considerations. The use of opioids is associated with adverse effects such as&#xD;
      nausea, pruritus, sedation, and occasionally respiratory depression.&#xD;
&#xD;
      Pregabalin is an anticonvulsant drug structurally related to the inhibitory neurotransmitter&#xD;
      gamma amino butyric acid, that exerts its action by binding to the α-2-δ subunit of the&#xD;
      voltage-dependent calcium channel. It reduces the release of the excitatory neurotransmitters&#xD;
      and inhibits the hyperalgesia and central sensitization.&#xD;
&#xD;
      A recent meta-analysis demonstrated that pregabalin reduce the postoperative 24 hours&#xD;
      cumulative opioid consumption and opioid-related adverse effects namely, vomiting and visual&#xD;
      disturbances after surgery. Compared with the use of pregabalin doses lower than 300 mg, the&#xD;
      use of doses higher than 300 mg even reduced opioid consumption by 35%.&#xD;
&#xD;
      It is not known if pregabalin is excreted in human milk. There is a case report on the&#xD;
      extensive excretion of pregabalin in breast milk, but with low measured concentrations in&#xD;
      infant as a consequence of maternal exposure during breast feeding. Food and Drug&#xD;
      Administration recommends to discontinue nursing or to discontinue pregabalin in nursing&#xD;
      mothers. Pre-delivery single exposure to pregabalin is expected to be safe for the newborns.&#xD;
&#xD;
      Up to the authors' best knowledge, this is the first clinical study on the efficacy and&#xD;
      safety of the administration of pregabalin before cesarean delivery.&#xD;
&#xD;
      We hypothesis that the preoperative administration of a single dose of pregabalin will&#xD;
      improve the quality of postoperative analgesia after cesarean delivery.&#xD;
&#xD;
      This placebo-controlled study aims to compare the effects of preoperative administrations of&#xD;
      single oral doses of pregabalin 150 mg and 300 mg on the postoperative pain scores,&#xD;
      cumulative patient controlled morphine consumptions, neonatal Apgar and neurologic and&#xD;
      adaptive capacity scores (NACS), and maternal and neonatal adverse effects in parturients&#xD;
      scheduled to elective Cesarean delivery under spinal anesthesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An independent investigator who will not be involved in the study will instruct the patients&#xD;
      preoperatively about the use of patient controlled analgesia and visual analogue scale to&#xD;
      assess the severity of postoperative pain (0 mm for no pain and100 mm for worst imaginable&#xD;
      pain).&#xD;
&#xD;
      Anaesthetic management will be standardized. Oral ranitidine 150 mg and metoclopramide 10 mg&#xD;
      will be given the night before and on the morning of surgery, with 0.3 mol/L sodium citrate&#xD;
      30 mL given 15 min before induction.&#xD;
&#xD;
      Ninety minutes before surgery, subjects will be allocated randomly into three groups by&#xD;
      drawing sequentially numbered sealed opaque envelopes containing a software-generated&#xD;
      randomization code to the placebo (n = 45), pregabalin 150 mg (n = 45) and the pregabalin 300&#xD;
      mg (n = 45) groups. The placebo and pregabalin capsules look identical and will be prepared&#xD;
      by a local pharmacy. An anaesthesiologist not otherwise involved in the study and who will be&#xD;
      blinded to treatment regimen will provide perioperative care. An independent investigator&#xD;
      will collect perioperative data. All staff in the operating room will be unaware of patient&#xD;
      allocation group.&#xD;
&#xD;
      Maternal monitoring will include electrocardiography, non-invasive blood pressure, and pulse&#xD;
      oximetry. Left uterine displacement will be maintained.&#xD;
&#xD;
      Spinal anesthesia will be performed in all cases in sitting position at L3-L4 or L4-L5 spaces&#xD;
      with hyperbaric bupivacaine 0.5% (12.5 mg) and fentanyl 20 µg. After the umbilical cord is&#xD;
      clamped, a 10 IU infusion of oxytocin in 500 mL of lactated Ringer's solution will be&#xD;
      infused.&#xD;
&#xD;
      A paediatrician blinded to study group allocation will record Apgar scores at 1 and 5 min,&#xD;
      umbilical cord blood gas analysis and NACS at 15 min, 2h, 24 and 48 h after delivery. NACS&#xD;
      gives a maximum of 40 with a score &gt;35 denoting vigor.The percentage of infants scoring &lt;35&#xD;
      will be determined.&#xD;
&#xD;
      Postoperative analgesic regime will be standardized in all patients with 12-hourly&#xD;
      intramuscular diclofenac 75 mg started immediately at the end of surgery and morphine via&#xD;
      patient-controlled analgesia (PCA): 1 mg bolus with an 8 minutes lockout. Postoperative&#xD;
      nausea or vomiting will be treated with intravenous metoclopramide 10 mg as required.&#xD;
&#xD;
      Statistical analysis:&#xD;
&#xD;
      Based on a previous study,7 the mean postoperative cumulative morphine consumption at 24 h&#xD;
      after caesarean delivery was 38 mg with a standard deviation of 14 mg. An a priori power&#xD;
      analysis indicated that 45 subjects were required in each group to detect a 25% reduction in&#xD;
      the cumulative morphine consumption at 24 h after caesarean delivery, that was assumed to&#xD;
      have a clinically significant effect, with a type-I error of 0.0167 (0.05/3 possible&#xD;
      comparisons) and a power of 90%. Additional patients (10%) were included for a final sample&#xD;
      size of 150 patients to account for patient dropout during the course of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cumulative patient controlled morphine consumptions</measure>
    <time_frame>24 hours after delivery</time_frame>
    <description>cumulative patient controlled morphine consumptions 24 hours after delivery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative pain scores</measure>
    <time_frame>1, 4, 6, 12, 24 and 48 hours after delivery</time_frame>
    <description>visual analogue scale to assess the severity of postoperative pain (0 mm for no pain and100 mm for worst imaginable pain) at rest and on movement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal Apgar scores</measure>
    <time_frame>1 and 5 min aftr delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurologic and adaptive capacity scores</measure>
    <time_frame>at 15 min, 2h, 24 and 48 h after delivery</time_frame>
    <description>NACS gives a maximum of 40 with a score &gt;35 denoting vigor.The percentage of infants scoring &lt;35 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal sedation</measure>
    <time_frame>every two hours after delivery, for 48 hours after delivery</time_frame>
    <description>sedation (0, alert; 1, somnolent easy to arouse; 2, somnolent difficult to arouse or asleep; 3, not arousable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal nausea and vomiting</measure>
    <time_frame>at 24 hours after delivery</time_frame>
    <description>nausea and vomiting (0: no nausea; 1: nausea no vomiting; 2: nausea and vomiting),</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse effects</measure>
    <time_frame>24 hours after delivery</time_frame>
    <description>difficulties in lactation, pruritus, dry mouth, flatulence, hypoglycaemia, dizziness, somnolence, ataxia, vertigo, confusion, incoordination, tremor, dyspnoea, blurred or abnormal vision</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Uncomplicated Singleton Pregnancies</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>receive two identical placebo capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin 150 mg group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one capsule of pregabalin 150 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin 300 mg group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>two capsules of pregabalin 150 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Ninety minutes before surgery, the parturients receive two identical placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 300 mg group</intervention_name>
    <description>Ninety minutes before surgery, the parturients receive two capsules of pregabalin 150 mg</description>
    <arm_group_label>Pregabalin 300 mg group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 150 mg group</intervention_name>
    <description>Ninety minutes before surgery, the parturients receive one capsule of pregabalin 150 mg and one placebo capsule</description>
    <arm_group_label>Pregabalin 150 mg group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  spinal anesthesia&#xD;
&#xD;
          -  elective cesarean delivery&#xD;
&#xD;
          -  breech presentation&#xD;
&#xD;
          -  cephalopelvic disproportion&#xD;
&#xD;
          -  previous caesarean delivery&#xD;
&#xD;
          -  American Society of Anesthesiologists class I and II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  communication barriers&#xD;
&#xD;
          -  cardiovascular diseases&#xD;
&#xD;
          -  renal diseases&#xD;
&#xD;
          -  hepatic diseases&#xD;
&#xD;
          -  endocrinal diseases&#xD;
&#xD;
          -  neuropsychiatric diseases&#xD;
&#xD;
          -  morbid obesity&#xD;
&#xD;
          -  diabetes mellitus&#xD;
&#xD;
          -  anaemia&#xD;
&#xD;
          -  bleeding disorders&#xD;
&#xD;
          -  prolonged P-R interval&#xD;
&#xD;
          -  hypersensitivity to pregabalin&#xD;
&#xD;
          -  receiving pregabalin&#xD;
&#xD;
          -  receiving anticonvulsants&#xD;
&#xD;
          -  receiving antidepressants&#xD;
&#xD;
          -  receiving antipsychotics&#xD;
&#xD;
          -  alcohol or drug abuse&#xD;
&#xD;
          -  Opiates abuse&#xD;
&#xD;
          -  benzodiazepines during the last week&#xD;
&#xD;
          -  pregnancy-induced hypertension&#xD;
&#xD;
          -  evidence of intrauterine growth restriction&#xD;
&#xD;
          -  fetal compromise&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samah A El Kenany, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anethesiology Dept, College of Medicine, Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed R El Tahan, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>College of Medicine, Mansoura University</name>
      <address>
        <city>Mansoura</city>
        <state>DK</state>
        <zip>050</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mansoura University Hospitals</name>
      <address>
        <city>Mansoura</city>
        <state>DK</state>
        <zip>050</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>October 28, 2012</study_first_submitted>
  <study_first_submitted_qc>October 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2012</study_first_posted>
  <last_update_submitted>July 29, 2015</last_update_submitted>
  <last_update_submitted_qc>July 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Mohamed R El Tahan</investigator_full_name>
    <investigator_title>Associate Professor of Anesthesiology &amp; SICU</investigator_title>
  </responsible_party>
  <keyword>caesarean delivery</keyword>
  <keyword>spinal anesthesia</keyword>
  <keyword>pregabalin</keyword>
  <keyword>postoperative pain</keyword>
  <keyword>morphine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

